Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFS NASDAQ:CLPT NASDAQ:ESTA NASDAQ:MDXG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$25.65$22.39$19.10▼$29.55$1.23B1.76484,255 shs541,408 shsCLPTClearPoint Neuro$10.64+1.3%$11.20$9.76▼$19.22$302.46M0.85317,761 shs255,127 shsESTAEstablishment Labs$41.76+2.7%$40.98$26.56▼$50.85$1.21B0.83527,505 shs191,308 shsMDXGMiMedx Group$7.16+1.1%$6.67$5.47▼$10.14$1.06B1.79686,046 shs371,007 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions-1.00%+4.69%+13.60%+15.23%+1.38%CLPTClearPoint Neuro-1.87%-6.42%-6.50%-16.27%-11.62%ESTAEstablishment Labs-6.81%+6.30%-4.13%+10.19%-10.93%MDXGMiMedx Group-3.15%-1.53%+4.58%+4.58%+2.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLFSBioLife Solutions2.6518 of 5 stars2.63.00.00.04.12.50.6CLPTClearPoint Neuro2.1296 of 5 stars3.51.00.00.03.20.80.6ESTAEstablishment Labs1.8558 of 5 stars3.40.00.00.01.92.50.6MDXGMiMedx Group3.3331 of 5 stars3.54.00.00.03.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 3.13Buy$31.2921.97% UpsideCLPTClearPoint Neuro 3.00Buy$19.6784.84% UpsideESTAEstablishment Labs 2.83Moderate Buy$56.5035.30% UpsideMDXGMiMedx Group 3.00Buy$12.0067.60% UpsideCurrent Analyst Ratings BreakdownLatest CLPT, BLFS, MDXG, and ESTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025ESTAEstablishment LabsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.008/11/2025BLFSBioLife SolutionsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/8/2025BLFSBioLife SolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $32.008/1/2025CLPTClearPoint NeuroStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.007/31/2025MDXGMiMedx GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$11.00 ➝ $12.007/22/2025BLFSBioLife SolutionsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$30.007/16/2025ESTAEstablishment LabsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $70.007/15/2025MDXGMiMedx GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$11.007/9/2025ESTAEstablishment LabsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$38.00 ➝ $47.006/13/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$48.00(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$82.25M14.94$0.12 per share211.49$7.52 per share3.41CLPTClearPoint Neuro$33.59M9.00N/AN/A$0.92 per share11.57ESTAEstablishment Labs$177.42M6.82N/AN/A$1.90 per share21.98MDXGMiMedx Group$363.77M2.91$0.32 per share22.06$1.31 per share5.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$20.18M-$0.12N/AN/AN/A-5.39%0.16%0.14%11/11/2025 (Estimated)CLPTClearPoint Neuro-$18.91M-$0.81N/AN/AN/A-66.15%-94.44%-51.58%11/6/2025 (Estimated)ESTAEstablishment Labs-$84.60M-$3.05N/AN/AN/A-49.89%-224.34%-25.53%11/6/2025 (Estimated)MDXGMiMedx Group$42.42M$0.2134.1022.38N/A8.84%23.03%17.09%10/29/2025 (Estimated)Latest CLPT, BLFS, MDXG, and ESTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CLPTClearPoint Neuro-$0.20-$0.21-$0.01-$0.21$9.20 million$9.22 million8/7/2025Q2 2025BLFSBioLife Solutions-$0.02-$0.33-$0.31-$0.33$23.71 million$25.42 million8/7/2025Q2 2025ESTAEstablishment Labs-$0.54-$0.57-$0.03-$0.57$50.80 million$51.30 million7/30/2025Q2 2025MDXGMiMedx Group$0.06$0.10+$0.04$0.06$90.79 million$98.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/ACLPTClearPoint NeuroN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife SolutionsN/A4.433.45CLPTClearPoint Neuro1.467.306.45ESTAEstablishment Labs9.712.841.67MDXGMiMedx Group0.084.393.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%CLPTClearPoint Neuro30.08%ESTAEstablishment Labs72.91%MDXGMiMedx Group79.15%Insider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%CLPTClearPoint Neuro6.97%ESTAEstablishment Labs11.09%MDXGMiMedx Group1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.90 million46.85 millionOptionableCLPTClearPoint Neuro11028.43 million26.69 millionOptionableESTAEstablishment Labs1,01828.97 million25.66 millionOptionableMDXGMiMedx Group870147.96 million145.44 millionOptionableCLPT, BLFS, MDXG, and ESTA HeadlinesRecent News About These CompaniesMiMedx Group, Inc $MDXG Shares Purchased by Algert Global LLCAugust 26 at 4:05 AM | marketbeat.comMiMedx Group, Inc $MDXG Shares Acquired by Deutsche Bank AGAugust 23 at 3:55 AM | marketbeat.comMiMedx Group, Inc (NASDAQ:MDXG) Shares Acquired by Meros Investment Management LPAugust 18, 2025 | marketbeat.comKoss Olinger Consulting LLC Raises Stake in MiMedx Group, Inc (NASDAQ:MDXG)August 11, 2025 | marketbeat.comFederated Hermes Inc. Decreases Stake in MiMedx Group, Inc (NASDAQ:MDXG)August 11, 2025 | marketbeat.comThere May Be Reason For Hope In MiMedx Group's (NASDAQ:MDXG) Disappointing EarningsAugust 7, 2025 | finance.yahoo.comAnalysts Conflicted on These Healthcare Names: Moderna (MRNA) and MiMedx Group (MDXG)August 5, 2025 | theglobeandmail.comMiMedx Group Inc. Reports Record Earnings and GrowthAugust 4, 2025 | theglobeandmail.comMiMedx Group (MDXG) Receives a Buy from Northland SecuritiesAugust 4, 2025 | theglobeandmail.comPhocas Financial Corp. Buys 202,265 Shares of MiMedx Group, Inc (NASDAQ:MDXG)August 4, 2025 | marketbeat.comMiMedx Group (NASDAQ:MDXG) Stock Rating Upgraded by Wall Street ZenAugust 3, 2025 | marketbeat.comResults: MiMedx Group, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesAugust 2, 2025 | finance.yahoo.comCantor Fitzgerald Forecasts Higher Earnings for MiMedx GroupAugust 2, 2025 | marketbeat.comNorthland Capmk Raises Earnings Estimates for MiMedx GroupAugust 2, 2025 | marketbeat.comMiMedx Group (NASDAQ:MDXG) Shares Gap Up Following Analyst UpgradeAugust 1, 2025 | marketbeat.comCantor Fitzgerald Forecasts Strong Price Appreciation for MiMedx Group (NASDAQ:MDXG) StockAugust 1, 2025 | marketbeat.comMiMedx Group, Inc. (MDXG) Q2 2025 Earnings Call TranscriptJuly 30, 2025 | seekingalpha.comMiMedx (MDXG) Q2 Earnings and Revenues Beat EstimatesJuly 30, 2025 | zacks.comMIMEDX Announces Record Second Quarter 2025 Operating and Financial ResultsJuly 30, 2025 | globenewswire.comMIMEDX Announces Strategic Collaboration with Vaporox, Inc.July 30, 2025 | globenewswire.comSA analyst upgrades/downgrades: OXY, AMZN, MDXG, CHTRJuly 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLPT, BLFS, MDXG, and ESTA Company DescriptionsBioLife Solutions NASDAQ:BLFS$25.65 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$25.64 -0.01 (-0.06%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.ClearPoint Neuro NASDAQ:CLPT$10.64 +0.14 (+1.33%) Closing price 04:00 PM EasternExtended Trading$10.65 +0.01 (+0.09%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Establishment Labs NASDAQ:ESTA$41.76 +1.10 (+2.71%) Closing price 04:00 PM EasternExtended Trading$41.86 +0.11 (+0.25%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.MiMedx Group NASDAQ:MDXG$7.16 +0.08 (+1.13%) Closing price 04:00 PM EasternExtended Trading$7.18 +0.01 (+0.21%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Just Had Its Best Day in 2 Months—Here’s What It Means Reynolds Consumer Products Stock Price: Insiders Signal a Bottom Ubiquiti's 30% Jump: Why This Was a Turnaround, Not Just a Trend Southern Company: From Nuclear Risk to AI Reward BJ’s Wholesale Club Pulls Back to Trend: It’s Time for an Entry Why Sprouts Farmers Market is Buying $1 Billion of Its Own Stock Time for Cleveland-Cliffs Stock to Break Out? Markets Say Yes As the Market Rotates, This Healthcare ETF Is Leading the Way Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.